Results 281 to 290 of about 1,404,058 (313)
Some of the next articles are maybe not open access.
Differential expression of matrix metalloproteinases and their inhibitors in non-small cell lung cancer
The Journal of Pathology, 2000 In a comprehensive immunohistochemical study of the expression of ten metalloproteinases (MMPs) and their four inhibitors (TIMPs) in 115 non-small cell lung carcinomas (NSCLCs), the findings have been correlated with the histological and clinical features of the tumours.P, Thomas, R, Khokha, F A, Shepherd, R, Feld, M S, Tsao +4 moreopenaire +2 more sourcesNon-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.
The Journal of the National Comprehensive Cancer Network, 2022 NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non-Small Cell Lung Cancer (NSCLC) provide recommended management for patients with NSCLC, including diagnosis, primary treatment, surveillance for relapse, and subsequent treatment ...D. Ettinger, D. Wood, D. Aisner, W. Akerley, J. Bauman, Ankit Bharat, D. Bruno, Joe Y. Chang, L. Chirieac, T. D’amico, M. Decamp, T. Dilling, J. Dowell, S. Gettinger, T. Grotz, M. Gubens, A. Hegde, R. Lackner, M. Lanuti, Jules Lin, B. Loo, C. Lovly, F. Maldonado, E. Massarelli, D. Morgensztern, T. Ng, G. Otterson, J. Pacheco, S. Patel, Gregory Riely, J. Riess, S. Schild, T. Shapiro, Aditi P. Singh, J. Stevenson, A. Tam, T. Tanvetyanon, J. Yanagawa, Stephen C. Yang, E. Yau, K. Gregory, M. Hughes +41 moresemanticscholar +1 more sourceRandomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer
Journal of Clinical Oncology, 2023 PURPOSE To investigate the efficacy and safety of bevacizumab plus carboplatin and paclitaxel in patients with advanced or recurrent non-small-cell lung cancer. PATIENTS AND METHODS In a phase II trial, 99 patients were randomly assigned to bevacizumab 7.David H. Johnson, L. Fehrenbacher, W. Novotny, R. Herbst, J. Nemunaitis, D. Jablons, C. Langer, R. Devore, J. Gaudreault, L. Damico, E. Holmgren, F. Kabbinavar +11 moresemanticscholar +1 more sourcePembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
The Lancet, 2019 BACKGROUND
First-line pembrolizumab monotherapy improves overall and progression-free survival in patients with untreated metastatic non-small-cell lung cancer with a programmed death ligand 1 (PD-L1) tumour proportion score (TPS) of 50% or greater.T. Mok, Yi‐Long Wu, I. Kudaba, D. Kowalski, B. Cho, H. Turna, G. Castro, V. Srimuninnimit, K. Laktionov, I. Bondarenko, K. Kubota, G. Lubiniecki, Jin Zhang, D. Kush, G. Lopes, G. Adamchuk, M. Ahn, A. Alexandru, O. Altundag, A. Alyasova, O. Andrusenko, K. Aoe, A. Araújo, O. Aren, O. Rodriguez, T. Ativitavas, Oscar Avendano, F. Barata, C. Barrios, C. Beato, Per Bergstrom, D. Betticher, L. Bolotina, Michiel Botha, Sayeuri Buddu, C. Caglevic, A. Cardona, H. Castro, F. Senler, Carlos Alexandre Sydow Cerny, A. Česas, G. Chan, Jian-hua Chang, Gongyan Chen, Xi Chen, S. Cheng, Ying Cheng, N. Cherciu, C. Chiu, S. Cicėnas, D. Ciurescu, G. Cohen, Marcos André Costa, P. Danchaivijitr, F. D. Angelis, S. Azevedo, M. Dediu, Ts Deliverski, P. Marchi, Flor de The Bustamante Valles, Z. Ding, Boyan Doganov, L. Dreosti, R. Duarte, Regina T Edusma-Dy, S. Emelyanov, M. Erman, Yun Fan, L. Fein, Jifeng Feng, D. Fenton, G. Fernandes, C. Ferreira, F. Franke, H. Freitas, Y. Fujisaka, H. Galindo, Christina Galvez, D. Ganea, N. Gil, G. Girotto, E. Goker, T. Goksel, Gonzalo Gomez Aubin, Luis Gomez Wolff, H. Griph, M. Gumus, Jacqueline M. Hall, Greg Hart, L. Havel, Jianxing He, Yong He, C. Hernández, V. Hespanhol, T. Hirashima, Chung-man. Ho, A. Horiike, Y. Hosomi, K. Hotta, M. Hou, S. How, T. Hsia, Yi Hu, M. Ichiki, F. Imamura, O. Ivashchuk, Y. Iwamoto, J. Jaal, J. Jassem, Christa Jordaan, R. Juergens, D. Kaen, E. Kalinka‐Warzocha, N. Karaseva, B. Karaszewska, A. Każarnowicz, K. Kasahara, N. Katakami, T. Kato, T. Kawaguchi, J. Kim, K. Kishi, V. Kolek, Marchela Koleva, P. Kolman, L. Koubková, R. Kowalyszyn, D. Kowalski, K. Koynov, D. Ksienski, T. Kurata, G. Kuusk, L. Kuzina, I. Laczó, G. Ladrera, K. Laktionov, G. Landers, S. Lazarev, G. Lerzo, Krzysztof Lesniewski- Kmak, Wei Li, C. Liam, Igor Lifirenko, O. Lipatov, Xiaoqing Liu, Zhe Liu, S. Lo, Valéria Lopes, K. Lopez, Shun Lu, G. Martinengo, L. Mas, M. Matrosova, Rumyana Micheva, Z. Milanova, L. Miron, Tony Mok, M. Molina, S. Murakami, Y. Nakahara, Tien Quang Nguyen, T. Nishimura, A. Ochsenbein, T. Ohira, Ronny Ohman, C. Ong, G. Ostoros, X. Ouyang, E. Ovchinnikova, O. Ozyılkan, L. Petruželka, Xuan Dung Pham, P. Picon, B. Pikó, A. Poltoratsky, Olga Ponomarova, Patrice Popelkova, G. Purkalne, S. Qin, R. Ramlau, Bernardo Rappaport, Felipe Rey, E. Richardet, J. Roubec, P. Ruff, A. Rusyn, H. Saka, J. Salas, Mario Sandoval, L. Santos, T. Sawa, K. Seetalarom, M. Seker, N. Seki, Freddy Seolwane, L. Shepherd, Sergii Shevnya, A. Shimada, Y. Shparyk, I. Sinielnikov, D. Sirbu, O. Smaletz, João Paulo Holanda Soares, A. Sookprasert, G. Speranza, V. Sriuranpong, Zinaida Stara, W. Su, S. Sugawara, W. Szpak, Kazuhisa Takahashi, N. Takigawa, Hiroshi Tanaka, Jerry Tan Chun Bing, Q. Tang, P. Taranov, H. Tejada, L. Tho, Yoshitaro Torii, Dmytro Trukhyn, M. Turdean, H. Turna, Grygoriy Ursol, J. Vaňásek, M. Varela, M. Vallejo, Luis Vera, A. Victorino, T. Vlásek, I. Vynnychenko, Buhai Wang, Jie Wang, Kai Wang, Yilong Wu, Kazuhiko Yamada, Chih‐Hsin Yang, T. Yokoyama, T. Yokoyama, H. Yoshioka, F. Yumuk, A. Zambrano, J. Zarbá, Oleg Zarubenkov, Marius Žemaitis, Li Zhang, Xin Zhang, Jun Zhao, Caicun Zhou, Jianying Zhou, Qing Zhou, A. Zippelius +250 moresemanticscholar +1 more sourcePembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
The Lancet, 2016 R. Herbst, P. Baas, Dong-Wan Kim, E. Felip, J. Pérez-Gracia, Ji-Youn Han, J. Molina, Joo‐Hang Kim, C. D. Arvis, M. Ahn, M. Majem, M. Fidler, G. Castro, M. Garrido, G. Lubiniecki, Shentu Yue, E. Im, M. Dolled-Filhart, E. Garon +18 moresemanticscholar +1 more sourceIdentification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
Nature, 2007 M. Soda, Y. L. Choi, Munehiro Enomoto, S. Takada, Y. Yamashita, S. Ishikawa, Shin-ichiro Fujiwara, Hideki Watanabe, K. Kurashina, Hisashi Hatanaka, M. Bando, S. Ohno, Y. Ishikawa, H. Aburatani, T. Niki, Y. Sohara, Y. Sugiyama, H. Mano +17 moresemanticscholar +1 more sourceAlectinib in Resected ALK-Positive Non-Small-Cell Lung Cancer.
New England Journal of MedicineBACKGROUND
Platinum-based chemotherapy is the recommended adjuvant treatment for patients with resectable, ALK-positive non-small-cell lung cancer (NSCLC).Yi-Long Wu, R. Dziadziuszko, Jin Seok Ahn, F. Barlesi, M. Nishio, Dae Ho Lee, Jong-Seok Lee, Wenzhao Zhong, H. Horinouchi, Weimin Mao, Maximilian Hochmair, F. de Marinis, M. R. Migliorino, Igor Bondarenko, Shun Lu, Qun Wang, Tania Ochi Lohmann, Tingting Xu, A. Cardona, T. Ruf, Johannes Noe, Benjamin J Solomon +21 moresemanticscholar +1 more source
